8-K filing — Perspective Therapeutics, Inc. (CATX)
Filed: 2026-09-08 AccNo: 0001193125-26-385362 Size: 24 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Perspective Therapeutics Announces Its Updated Data On The VMT-α-NET Program Have Been Accepted For Presentation At EORTC-NCI-AACR Symposium 2026 On Molecular Targets And Cancer Therapeutics, November 18-20; Conference Plans To Release Further Details For Abstracts On November 4
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11
BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.